Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.140
0.00 (0.00%)
Jan 29, 2026, 3:20 PM EST - Market open
Arbutus Biopharma Employees
Arbutus Biopharma had 44 employees as of December 31, 2024. The number of employees decreased by 29 or -39.73% compared to the previous year.
Employees
44
Change (1Y)
-29
Growth (1Y)
-39.73%
Revenue / Employee
$331,955
Profits / Employee
-$960,841
Market Cap
796.22M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 44 | -29 | -39.73% | 44 | 0 |
| Dec 31, 2023 | 73 | -25 | -25.51% | 73 | 0 |
| Dec 31, 2022 | 98 | 11 | 12.64% | 96 | 2 |
| Dec 31, 2021 | 87 | 9 | 11.54% | 85 | 2 |
| Dec 31, 2020 | 78 | -2 | -2.50% | 76 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 837 |
| Valneva SE | 713 |
| KalVista Pharmaceuticals | 270 |
| Prime Medicine | 214 |
| Omeros | 202 |
| Kura Oncology | 192 |
| enGene Holdings | 82 |
| Nektar Therapeutics | 61 |
ABUS News
- 2 months ago - Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025 - GlobeNewsWire
- 6 months ago - Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus - GlobeNewsWire
- 9 months ago - Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 - GlobeNewsWire
- 10 months ago - Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - GlobeNewsWire
- 11 months ago - Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle - Market Watch